We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $75.62, moving -0.07% from the previous trading session. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow gained 0.02%, and the Nasdaq, a tech-heavy index, added 0.01%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 0.28% over the past month. This has was narrower than the Medical sector's loss of 1.58% and lagged the S&P 500's gain of 0.38% in that time.
Wall Street will be looking for positivity from Gilead Sciences as it approaches its next earnings report date. The company is expected to report EPS of $1.92, up 1.05% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $6.76 billion, down 3.94% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.64 per share and revenue of $26.78 billion, which would represent changes of -8.54% and -1.82%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% lower within the past month. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Gilead Sciences's current valuation metrics, including its Forward P/E ratio of 11.4. For comparison, its industry has an average Forward P/E of 17.7, which means Gilead Sciences is trading at a discount to the group.
Investors should also note that GILD has a PEG ratio of 0.81 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 2.18 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $75.62, moving -0.07% from the previous trading session. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow gained 0.02%, and the Nasdaq, a tech-heavy index, added 0.01%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 0.28% over the past month. This has was narrower than the Medical sector's loss of 1.58% and lagged the S&P 500's gain of 0.38% in that time.
Wall Street will be looking for positivity from Gilead Sciences as it approaches its next earnings report date. The company is expected to report EPS of $1.92, up 1.05% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $6.76 billion, down 3.94% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.64 per share and revenue of $26.78 billion, which would represent changes of -8.54% and -1.82%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% lower within the past month. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Gilead Sciences's current valuation metrics, including its Forward P/E ratio of 11.4. For comparison, its industry has an average Forward P/E of 17.7, which means Gilead Sciences is trading at a discount to the group.
Investors should also note that GILD has a PEG ratio of 0.81 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 2.18 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.